Literature DB >> 19390566

Immunoregulatory functions of mTOR inhibition.

Angus W Thomson1, Hēth R Turnquist, Giorgio Raimondi.   

Abstract

The potent immunosuppressive action of rapamycin is commonly ascribed to inhibition of growth factor-induced T cell proliferation. However, it is now evident that the serine/threonine protein kinase mammalian target of rapamycin (mTOR) has an important role in the modulation of both innate and adaptive immune responses. mTOR regulates diverse functions of professional antigen-presenting cells, such as dendritic cells (DCs), and has important roles in the activation of effector T cells and the function and proliferation of regulatory T cells. In this Review, we discuss our current understanding of the mTOR pathway and the consequences of mTOR inhibition, both in DCs and T cells, including new data on the regulation of forkhead box P3 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390566      PMCID: PMC2847476          DOI: 10.1038/nri2546

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  149 in total

1.  Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation.

Authors:  Wilfried Reichardt; Christoph Dürr; Dominik von Elverfeldt; Eva Jüttner; Ulrike V Gerlach; Mayumi Yamada; Benjie Smith; Robert S Negrin; Robert Zeiser
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

2.  PSGL-1 and mTOR regulate translation of ROCK-1 and physiological functions of macrophages.

Authors:  Richard Fox; Thomas Q Nhan; G Lynn Law; David R Morris; W Conrad Liles; Stephen M Schwartz
Journal:  EMBO J       Date:  2007-01-24       Impact factor: 11.598

3.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.

Authors:  J Heitman; N R Movva; M N Hall
Journal:  Science       Date:  1991-08-23       Impact factor: 47.728

4.  Cyclosporin-A differentially affects apoptosis during in vivo rat thymocyte maturation.

Authors:  J G M C Damoiseaux; M P Defresne; C P M Reutelingsperger; P J C Van Breda Vriesman
Journal:  Scand J Immunol       Date:  2002-10       Impact factor: 3.487

5.  Akt regulates growth by directly phosphorylating Tsc2.

Authors:  Christopher J Potter; Laura G Pedraza; Tian Xu
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

6.  Mechanism of ribosomal p70S6 kinase activation by granulocyte macrophage colony-stimulating factor in neutrophils: cooperation of a MEK-related, THR421/SER424 kinase and a rapamycin-sensitive, m-TOR-related THR389 kinase.

Authors:  Jason A Lehman; Victor Calvo; Julian Gomez-Cambronero
Journal:  J Biol Chem       Date:  2003-05-11       Impact factor: 5.157

7.  Participation of mammalian target of rapamycin complex 1 in Toll-like receptor 2- and 4-induced neutrophil activation and acute lung injury.

Authors:  Emmanuel Lorne; Xia Zhao; Jaroslaw W Zmijewski; Gang Liu; Young-Jun Park; Yuko Tsuruta; Edward Abraham
Journal:  Am J Respir Cell Mol Biol       Date:  2009-01-08       Impact factor: 6.914

8.  The TSC-mTOR signaling pathway regulates the innate inflammatory response.

Authors:  Thomas Weichhart; Giuseppina Costantino; Marko Poglitsch; Margit Rosner; Maximilian Zeyda; Karl M Stuhlmeier; Thomas Kolbe; Thomas M Stulnig; Walter H Hörl; Markus Hengstschläger; Mathias Müller; Marcus D Säemann
Journal:  Immunity       Date:  2008-10-09       Impact factor: 31.745

9.  Rapamycin, but not cyclosporine or FK506, alters natural killer cell function.

Authors:  Lu-En Wai; Masato Fujiki; Saori Takeda; Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2008-01-15       Impact factor: 4.939

10.  Use of sirolimus (rapamycin) to treat refractory Crohn's disease.

Authors:  D C O Massey; F Bredin; M Parkes
Journal:  Gut       Date:  2008-09       Impact factor: 23.059

View more
  361 in total

1.  Rapamycin Prolongs Graft Survival and Induces CD4+IFN-γ+IL-10+ Regulatory Type 1 Cells in Old Recipient Mice.

Authors:  Markus Quante; Timm Heinbokel; Karoline Edtinger; Koichiro Minami; Hirofumi Uehara; Yeqi Nian; Haruhito Azuma; Reza Abdi; Abdallah Elkhal; Stefan G Tullius
Journal:  Transplantation       Date:  2018-01       Impact factor: 4.939

2.  Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.

Authors:  Jann N Sarkaria; Eva Galanis; Wenting Wu; Allan B Dietz; Timothy J Kaufmann; Michael P Gustafson; Paul D Brown; Joon H Uhm; Ravi D Rao; Laurence Doyle; Caterina Giannini; Kurt A Jaeckle; Jan C Buckner
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

Review 3.  The "other" mTOR complex: New insights into mTORC2 immunobiology and their implications.

Authors:  Helong Dai; Angus W Thomson
Journal:  Am J Transplant       Date:  2019-03-19       Impact factor: 8.086

4.  Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation.

Authors:  E Norsted Gregory; S Codeluppi; J A Gregory; J Steinauer; C I Svensson
Journal:  Neuroscience       Date:  2010-06-09       Impact factor: 3.590

Review 5.  The role of mTOR in memory CD8 T-cell differentiation.

Authors:  Koichi Araki; Ben Youngblood; Rafi Ahmed
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

6.  Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice.

Authors:  Ying Wang; Geoffrey Camirand; Yan Lin; Monica Froicu; Songyan Deng; Warren D Shlomchik; Fadi G Lakkis; David M Rothstein
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

7.  Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis.

Authors:  Jack T Lin; Emily A Stein; Michael T Wong; Krishna J Kalpathy; Leon L Su; Paul J Utz; William H Robinson; C Garrison Fathman
Journal:  Clin Immunol       Date:  2011-10-01       Impact factor: 3.969

Review 8.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

9.  Critical role of the mTOR pathway in development and function of myeloid-derived suppressor cells in lal-/- mice.

Authors:  Xinchun Ding; Hong Du; Mervin C Yoder; Cong Yan
Journal:  Am J Pathol       Date:  2013-11-26       Impact factor: 4.307

10.  Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells.

Authors:  Yanyan Wang; Gonghua Huang; Hu Zeng; Kai Yang; Richard F Lamb; Hongbo Chi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.